Papillary thyroid cancers (PTCs) are driven in about 50–60% of cases by the BRAFV600E mutation, while 5–20% of cases show fusion genes such as RET/PTC, PAX8-PPARG, and NTRK1/3 rearrangements, and 10–15% show RAS mutations (Cancer Genome Atlas Research 2014, Fagin & Wells 2016). This evidence concerns the gene RET and thyroid gland papillary carcinoma.